Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers found that steroidal 17β-carboxamides 1-4 significantly inhibited 5α-reductase enzyme activity and reduced prostate weight more effectively than finasteride in a hamster model, without toxic side effects, suggesting potential for treating benign prostatic hyperplasia.

BPH treatment improved with personalized medicine, new drugs, and less invasive surgeries.

Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

In this study, men using Propecia for alopecia showed normal erectile hemodynamics despite erectile dysfunction after stopping 5-alpha reductase inhibitors, while some BPH patients exhibited abnormal results potentially linked to vascular risk factors.

Finasteride may reduce prostate cancer risk.

This study describes the molecular conformation and intermolecular interactions in the crystalline structure of the compound C24H31BrO4.

This study found that the Mark Cuban Cost Plus Drug Company model offers substantial cost savings on men's health medications compared to Medicare and GoodRx, particularly for long-term treatments.

This study identified potent dual inhibitors of 5α-reductases 1 and 2 that may aid in designing new drugs for related diseases.

This study concluded that androgenetic alopecia was not a prognostic indicator for COVID-19, but hospitalization frequency increased in older patients with benign prostatic hyperplasia, supporting an androgen-mediated severity hypothesis.

This study proposes that the use of 5-alpha-reductase inhibitors for treating benign prostatic hyperplasia may contribute to poorer COVID-19 prognosis in males.

This study evaluated novel steroid compounds for their ability to inhibit 5α-reductase, showing that compound 16a significantly reduced rat prostate weight more than epristeride and exhibited excellent in vitro inhibitory potency, indicating its potential as a lead candidate for further benign prostatic hyperplasia drug research.

This laboratory study found that PI extract, along with its metabolites Ang and Mac, inhibited cell proliferation and protein expression linked to pathways involved in BPH, suggesting potential for therapeutic use, although the Ang-Mac combination showed no significant effect on apoptosis through the p53 pathway.

This cohort study using real-world data found no significant difference in the risk of developing prostate cancer between finasteride and dutasteride among patients with benign prostatic hyperplasia, despite previous suggestions that dutasteride might be more effective.

Long-term finasteride use may lead to earlier use of ED medication and lower prostate cancer diagnosis rates.

This study found that a new deoxycholic acid derivative may offer a similar prostatoprotective effect to finasteride with lower toxicity in rat models.

This study found that the compound androstane-17-carboxamide 6 may serve as a lead for new drugs to treat BPH and prostate cancer by reducing the weight of androgen-dependent glands.

This study will explore whether combination therapy with either dutasteride or finasteride and an α1 blocker is more effective than monotherapy for treating BPH, but it reports no new results.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

This study constructed a model to predict finasteride's inhibitory activity on 5α-reductase type 2 and calculated that a 1 μM plasma concentration, after 50 mg administration, matches prostate inhibition levels.

This study found that fruit extracts from certain Egyptian Sabal species demonstrated significant anti-androgenic activity and potential therapeutic effects against benign prostatic hyperplasia in rat models and cell lines.

This study concluded that pretreatment with finasteride or bicalutamide did not significantly affect the heat sensitivity of prostate cancer cells, although some cell lines showed increased viability at higher temperatures.

This study reports that comorbidities and anti-androgen therapy were associated with lower SARS-CoV-2 vaccination rates among patients with androgenetic alopecia, emphasizing the need to promote vaccination within this group.

This review discusses the role of 5α-reductase in prostate development and BPH, and reports no new clinical results; ongoing trials are exploring dual isozyme inhibitors for improved treatment efficacy.

This review explores the potential impact of SARS-CoV-2 on benign prostatic hyperplasia and related lower urinary tract symptoms but reports no new clinical results, emphasizing the need for further studies to quantify these changes.

This review describes how dutasteride, a dual 5alpha-reductase inhibitor, has improved outcomes in benign prostatic hyperplasia and is being studied for prostate cancer prevention, without new data reported.

This review discusses the use of 5α-reductase inhibitors, particularly finasteride, for treating conditions like benign prostatic hyperplasia, male baldness, and hirsutism, and reports no new clinical results.

This study reported that newly synthesized phenanthridin-3-one derivatives effectively inhibit human steroid 5-α-reductase.

This study found that black cohosh extract BNO 1055 reduced testosterone-induced prostate and seminal vesicle growth in rats, suggesting it may contain potent 5α-reductase inhibitors useful for prostate cancer prevention.

This study suggests that endurance exercise training may alleviate hormonal and inflammatory factors associated with BPH in rats, although it does not improve autophagy regulation.

This review discusses the historical and current use of androgen manipulation for treating benign prostatic hyperplasia and reports no new clinical results.